Association between Parkinson’s disease and Helicobacter pylori

Journal of Clinical Neurology (Korea)

Volumn 12, Issue 2, 2016, Pages 147-150

  Çamcı, Gülşah ^a   Oğuz, Sıdıka ^b  

^a KOCAELI UNIVERSITY   (Turkey)

^b MARMARA UNIVERSITY   (Turkey)

Author keywords

Helicobacter pylori; Levodopa; Motor fluctuations; Parkinson s disease

Indexed keywords

EID: 84963626535     PISSN: 17386586     EISSN: 20055013     Source Type: Journal    
DOI: 10.3988/jcn.2016.12.2.147     Document Type: Review

References (35)

1. Memiş S. Parkinson hastalığı ve bakım. In: Durna Z, editor. Kronik Hastalıklar ve Bakım. İstanbul: Nobel Tıp Kitabevi, 2011;277.
2. Barnum CJ, Tansey MG. Neuroinflammation and non-motor symptoms: the dark passenger of Parkinson’s disease? Curr Neurol Neurosci Rep 2012;12:350-358.
3. Bu XL, Wang X, Xiang Y, Shen LL, Wang QH, Liu YH, et al. The association between infectious burden and Parkinson’s disease: a casecontrol study. Parkinsonism Relat Disord 2015;21:877-881.
4. Tan AH, Mahadeva S, Thalha AM, Gibson PR, Kiew CK, Yeat CM, et al. Small intestinal bacterial overgrowth in Parkinson’s disease. Parkinsonism Relat Disord 2014;20:535-540.
5. Chaudhuri KR, Healy DG, Schapira AH; National Institute for Clinical Excellence. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol 2006;5:235-245.
6. Simuni T, Sethi K. Nonmotor manifestations of Parkinson’s disease. Ann Neurol 2008;64 Suppl 2:S65-S80.
7. Lim SY, Lang AE. The nonmotor symptoms of Parkinson’s disease-an overview. Mov Disord 2010;25 Suppl 1:S123-S130.
8. McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med 2010;362:1597-1604.
9. Franceschi F, Gasbarrini A. Helicobacter pylori and extragastric diseases. Best Pract Res Clin Gastroenterol 2007;21:325-334.
10. Tan HJ, Goh KL. Extragastrointestinal manifestations of Helicobacter pylori infection: facts or myth? A critical review. J Dig Dis 2012;13:342-349.
11. Dobbs RJ, Charlett A, Dobbs SM, Weller C, Peterson DW. Parkinsonism: differential age-trend in Helicobacter pylori antibody. Aliment Pharmacol Ther 2000;14:1199-1205.
12. Pierantozzi M, Pietroiusti A, Brusa L, Galati S, Stefani A, Lunardi G, et al. Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology 2006;66:1824-1829.
13. Lee WY, Yoon WT, Shin HY, Jeon SH, Rhee PL. Helicobacter pylori infection and motor fluctuations in patients with Parkinson’s disease. Mov Disord 2008;23:1696-1700.
14. Dobbs RJ, Charlett A, Dobbs SM, Weller C, A IbrahimMA, Iguodala O, et al. Leukocyte-subset counts in idiopathic parkinsonism provide clues to a pathogenic pathway involving small intestinal bacterial overgrowth. A surveillance study. Gut Pathog 2012;4:12.
15. Tan AH, Mahadeva S, Marras C, Thalha AM, Kiew CK, Yeat CM, et al. Helicobacter pylori infection is associated with worse severity of Parkinson’s disease. Parkinsonism Relat Disord 2015;21:221-225.
16. Weller C, Charlett A, Oxlade NL, Dobbs SM, Dobbs RJ, Peterson DW, et al. Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 3: predicted probability and gradients of severity of idiopathic parkinsonism based on H. pylori antibody profile. Helicobacter 2005;10:288-297.
17. Charlett A, Dobbs RJ, Dobbs SM, Weller C, Brady P, Peterson DW. Parkinsonism: siblings share Helicobacter pylori seropositivity and facets of syndrome. Acta Neurol Scand 1999;99:26-35.
18. Blaecher C, Smet A, Flahou B, Pasmans F, Ducatelle R, Taylor D, et al. Significantly higher frequency of Helicobacter suis in patients with idiopathic parkinsonism than in control patients. Aliment Pharmacol Ther 2013;38:1347-1353.
19. Dobbs SM, Dobbs RJ, Weller C, Charlett A. Link between Helicobacter pylori infection and idiopathic parkinsonism. Med Hypotheses 2000;55:93-98.
20. Schulz JD, Hawkes EL, Shaw CA. Cycad toxins, Helicobacter pylori and parkinsonism: cholesterol glucosides as the common denomenator. Med Hypotheses 2006;66:1222-1226.
21. Dobbs RJ, Dobbs SM, Weller C, Charlett A, Bjarnason IT, Curry A, et al. Helicobacter hypothesis for idiopathic parkinsonism: before and beyond. Helicobacter 2008;13:309-322.
22. Kountouras J, Zavos C, Polyzos SA, Deretzi G, Vardaka E, GiartzaTaxidou E, et al. Helicobacter pylori infection and Parkinson’s disease: apoptosis as an underlying common contributor. Eur J Neurol 2012;19:56.
23. Fasano A, Bove F, Gabrielli M, Ragazzoni E, Fortuna S, Tortora A, et al. Liquid melevodopa versus standard levodopa in patients with Parkinson disease and small intestinal bacterial overgrowth. Clin Neuropharmacol 2014;37:91-95.
24. Pfeiffer R. Beyond here be dragons: SIBO in Parkinson’s disease. Mov Disord 2013;28:1764-1765.
25. Lahner E, Annibale B, Delle Fave G. Systematic review: Helicobacter pylori infection and impaired drug absorption. Aliment Pharmacol Ther 2009;29:379-386.
26. Niehues M, Hensel A. In-vitro interaction of L-dopa with bacterial adhesins of Helicobacter pylori: an explanation for clinicial differences in bioavailability? J Pharm Pharmacol 2009;61:1303-1307.
27. Lyte M. Microbial endocrinology as a basis for improved L-DOPA bioavailability in Parkinson’s patients treated for Helicobacter pylori. Med Hypotheses 2010;74:895-897.
28. Pierantozzi M, Pietroiusti A, Sancesario G, Lunardi G, Fedele E, Giacomini P, et al. Reduced L-dopa absorption and increased clinical fluctuations in Helicobacter pylori-infected Parkinson’s disease patients. Neurol Sci 2001;22:89-91.
29. Rahne KE, Tagesson C, Nyholm D. Motor fluctuations and Helicobacter pylori in Parkinson’s disease. J Neurol 2013;260:2974-2980.
30. Dobbs SM, Charlett A, Dobbs RJ, Weller C, Iguodala O, Smee C, et al. Antimicrobial surveillance in idiopathic parkinsonism: indication-specific improvement in hypokinesia following Helicobacter pylori eradication and non-specific effect of antimicrobials for other indications in worsening rigidity. Helicobacter 2013;18:187-196.
31. Bjarnason IT, Charlett A, Dobbs RJ, Dobbs SM, Ibrahim MA, Kerwin RW, et al. Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 2: response of facets of clinical idiopathic parkinsonism to Helicobacter pylori eradication. A randomized, double-blind, placebo-controlled efficacy study. Helicobacter 2005;10:276-287.
32. Dobbs SM, Dobbs RJ, Weller C, Charlett A, Bjarnason IT, Lawson AJ, et al. Differential effect of Helicobacter pylori eradication on time-trends in brady/hypokinesia and rigidity in idiopathic parkinsonism. Helicobacter 2010;15:279-294.
33. Hashim H, Azmin S, Razlan H, Yahya NW, Tan HJ, Manaf MR, et al. Eradication of Helicobacter pylori infection improves levodopa action, clinical symptoms and quality of life in patients with Parkinson’s disease. PLoS One 2014;9:e112330.
34. Narożańska E, Białecka M, Adamiak-Giera U, Gawrońska-Szklarz B, Sołtan W, Schinwelski M, et al. Pharmacokinetics of levodopa in patients with Parkinson disease and motor fluctuations depending on the presence of Helicobacter pylori infection. Clin Neuropharmacol 2014;37:96-99.
35. ClinicalTrials.gov (US). Helicobacter pylori eradication in Parkinson’s disease: a double-blind randomised placebo controlled trial [Internet]. Kuala Lumpur: University of Malaya; 2014 [cited 2015 Sep 16]. Available from: https://clinicaltrials.gov/show/NCT02108704.